Hacker News Reader

"Semaglutide attenuates a proteomics-based dementia risk signature "

ie : clinically meaningless.

The company behind this, Novo Nordisk is increasingly desperate, as tirzepatide destroys the semaglutide revenue stream and the consequent job losses decimate the company

View on HN

Their operating profit was up 11% on a margin of 44% according to their recent quarterly release, and they beat EPS by 23%. They were in a little trouble in the stock market a few years ago as competitors came online, but they are doing pretty well right now.

They have launched new semaglutide oral products which are growing faster than previous products, and they have multiple drugs in the research pipeline in late phases.

Can you elaborate on your claims? As it currently stands, I’m only reading meaningless drivel from you.

Reply on news.ycombinator.com